Hims & Hers stock whipsaws on $49 Wegovy-copy pill as legal threats cloud next move
Hims & Hers Health shares fell 3.2% to $23.63 after launching a $49 compounded semaglutide pill, undercutting Novo Nordisk’s oral Wegovy. The stock swung between $22.98 and $29.44 on heavy volume. Novo threatened legal action, calling the compounding illegal. Hims reports earnings Feb. 23.